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Inflammatory events occurring in the distal part of an injured peripheral nerve have, nowadays, a 
great resonance. Investigating the timing of action of the several cytokines in the important stages 
of Wallerian degeneration helps to understand the regenerative process and design pharmacologic 
intervention that promotes and expedites recovery. The complex and synergistic action of 
inflammatory cytokines finally promotes axonal regeneration. Cytokines can be divided into pro- and 
anti-inflammatory cytokines that upregulate and downregulate, respectively, the production of 
inflammatory mediators. While pro-inflammatory cytokines are expressed in the first phase of 
Wallerian degeneration and promote the recruitment of macrophages, anti-inflammatory cytokines 
are expressed after this recruitment and downregulate the production of all cytokines, thus 
determining the end of the process. In this review, we describe the major inflammatory cytokines 
involved in Wallerian degeneration and the early phases of nerve regeneration. In particular, we 
focus on interleukin-1, interleukin-2, interleukin-6, tumor necrosis factor-β, interleukin-10 and 
transforming growth factor-β. 
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Research Highlights  
(1) Inflammatory cytokines activated after nerve injury lead to a characteristic series of cellular and 
molecular events that facilitate axon regeneration and, eventually, re-innervation of target tissues.  
(2) After peripheral nerve injury, pro- and anti-inflammatory cytokines are produced by both immune 
and non-immune cells resident in the distal part of the injured nerve or recruited from blood 
circulation. As surgically repaired nerves still do not give complete recovery of nerve function, better 
knowledge of these inflammatory events should provide new therapeutic perspectives that improve 
and accelerate peripheral nerve regeneration and functional recovery. 
 
Abbreviations 
WD, Wallerian degeneration; SCs, Schwann cells; TNF-α, tumor necrosis factor-α; TGF-β, 
transforming growth factor-β; NCAM, Neural Cell Adhesion Molecule; SCIP, Suppressed 
cAMP-inducible POU-domain protein.
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INTRODUCTION 
    
Peripheral nerve damage is a common injury; although 
the fibres retain a considerable regeneration potential in 
the adult, recovery is usually rather poor, especially in 
cases of large nerve defects. The clinical outcome of 
nerve lesions is far from satisfactory and functional 
recovery is seldom complete. It is necessary to 
understand more fully the biological mechanisms that 
underlie the complex sequence of events that follows 
nerve damage, but also to define the best strategies for 
optimizing post-traumatic nerve regeneration. 
After peripheral nerve injuries, cellular and molecular 
events that occur in the distal part (Wallerian 
degeneration, WD) and stimulate axonal regeneration[1-3]. 
Axons in the distal part of the injured nerve remain intact 
for some days before granular disintegration of the 
cytoskeleton[4]. During the first 24 hours following injury 
and before the arrival of blood-derived macrophages, 
Schwann cells (SCs) control demyelination by degrading 
myelin basic protein[5]. 
Following the loss of contact of the glia with the axon and 
the activation of inflammatory events, myelin sheath 
disintegration, SC proliferation and rearrangement of the 
band of Büngner occur.  
The breakdown of the blood-nerve barrier allows blood 
factors and cells that facilitate tissue repair to enter the 
nerve in the first 2 weeks. Permeability of the 
blood-nerve barrier increases again after 4 weeks in 
order to regain homeostasis after WD[6]. 
Immediately after nerve injury, the 
important phenomenon of macrophage recruitment 
occurs to aid debris elimination and tissue remodeling[7]. 
The rapid clearance of degenerated myelin activated by 
Schwann cells (SCs) and macrophages is a crucial step 
for successful nerve regeneration. In fact, during WD, 
SCs and macrophages phagocytize the degenerated 
myelin and moreover produce cytokines and 
neurotrophic factors necessary for axon regeneration.   
The inflammatory reaction is mainly due to macrophages. 
Signaling pathways between primary sensory neurons, 
SCs and immune cells are highly intertwined, and 
cytokines and chemokines are central components in 
this complex network[8]. 
Recent studies have been focused on inflammatory 
events occurring during WD[9-11]. There are several 
different factors produced by macrophages and SCs that 
play an important role during degeneration and 
regeneration of a peripheral nerve. 
Activation of immune and immune-like glial cells in the 
injured nerve leads to the release of both pro- and 
anti-inflammatory cytokines[5]. Pro-inflammatory 
cytokines [e.g. interleukin (IL)-1, -2, -6 and tumor 
necrosis factor (TNF)] are expressed principally in the 
first phase of WD, promoting the recruitment of 
macrophages from 2 to 3 days after the injury, while 
anti-inflammatory cytokines [(e.g. IL-10 and transforming 
growth factor-β (TGF-β)] are expressed after 
macrophages recruitment[11] and have the role of 
attenuating the inflammatory process. 
This review focused on the role of the inflammatory 
cytokines in WD and in the early phases of regeneration 
of a peripheral nerve. 
 
 
TNF-α 
 
TNF-α is a pro-inflammatory cytokine expressed as a 
26-kDa transmembrane protein that can be cleaved to 
release a 17-kDa soluble form. It is widely considered as 
the prototypical pro-inflammatory cytokine because it 
regulates inflammatory responses after injury to the 
peripheral or central nervous system[12-14], initiating the 
activation cascade of other cytokines and growth factors[15]. 
TNF-α exerts its action via its receptors, TNF-α receptor 
1 (TNF-R1) and the lower affinity TNFR2[16], which are 
expressed in both glia and neurons[17]. TNF-R1 contains 
an intracellular “death domain” and is responsible for 
controlling the neuronal death. TNF-R2 contributes to 
neuroprotection due to his relation to T-cell development 
and the proliferation[12,13,16-18].  
In the peripheral nervous system, the endogenous 
TNF-α released by SCs, resident macrophages and mast 
cells occurs after nerve damage. Immediately after 
peripheral nerve injury, TNF-α expression increases in 
the site of lesion[19-20] leading to a massive recruitment of 
macrophages[21-22]. Recruitment is probably mediated by 
metalloproteinase[23], or through the upregulation of 
adhesion molecules or cytokines[21].  
Shubayev’s group, after performing sciatic crush lesions 
in TNF-α and matrix metallopeptidase 9 (MMP-9) 
knockout mice, found fewer macrophages in the distal 
parts of the injury[23]. Furthermore, MMP-9 produced by 
SCs and endoneurial macrophages after TNF-α 
activation promote blood nerve barrier degradation and 
demyelination[23-24].   
Macrophages activated during WD phagocytose 
degenerating myelin, collaborate in the reorganization of 
the endoneurial space, and help remodel the 
extracellular matrix[10,25]. Infiltrating blood-derived cells 
also release additional TNF-α, resulting in a second peak 
3-5 days after injury[26]. 
The role of TNF-α in peripheral nerve injury has been 
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thoroughly investigated both in vivo and in vitro by many 
groups. Liefner and collegues[21] demonstrated in a 
transected sciatic nerve of TNF-α deficient mice that 
poor macrophage recruitment results in delayed myelin 
removal. Also Uncini and collegues[27] have 
demonstrated the role of TNF-α in blood-nerve barrier 
degradation; in fact they showed that the injection of 
TNF-α in an injured sciatic nerve of the rat resulted in the 
damage of the blood-nerve barrier and an inflammatory 
infiltration of the vessel walls, thus supporting the 
hypothesis of a direct chemotactic effect of TNF-α. 
Interestingly, two in vitro studies revealed the direct effect 
of TNF-α on SCs[20,28], showing that TNF-α decreases SC 
proliferation in a dose-dependent manner without 
affecting SCs viability. 
 
 
IL-1 
 
Another very important pro-inflammatory cytokine 
involved in the peripheral nerve injury process is the IL-1. 
IL-1, the product of a member of a superfamily of related 
genes, some of which generate proteins not involved in 
inflammation[29], causes the accumulation of arachidonic 
acid metabolites, upregulates inducible nitric oxide 
synthase, and sustains nitric oxide production. It is a 
polypeptide produced in 2 molecular forms, IL-1α and 
IL-1β; despite only a 26% amino acid homology, both 
forms can determine a wide variety of biological 
responses. In vitro, IL-1 activates T and B lymphocytes 
and induces a variety of lymphokines, interferons, and 
other cytokines, particularly TNF, for the induction of 
inflammatory changes, such as prostaglandin synthesis, 
activation of endothelial cells, and bone resorption. 
They are both synthesized as 31 kDa precursors, the 
processing of these molecules to their final mature form 
requiring a specific protease. Pro IL-1α remains in the 
cytosol in association with cytoskeletal structures, e.g. 
microtubules[30]. When the cells die, the pro-protein is 
released and can be processed by extracellular 
proteases, but can also be cleaved by the activation of 
calcium-dependent, membrane associated cysteine 
proteases called calpains[31]. Following synthesis, pro 
IL-1β remains in the cytosol and is only partially active. 
Its active form is secreted from the cell after the cleavage 
by ICE, the IL-1β converting enzyme[32-33]. 
Two IL-1 receptors and one accessory protein (IL-1 R-AcP) 
have been identified. They comprise 3 IgG-like domains, 
and share a significant homology to each other[30,34]. While 
the type I receptor (IL-IRI) transduces a signal, the type II 
receptor (IL-1RII) binds IL-1, but does not exhibit signal 
transduction; in fact, the receptor IL-1RII acts as a 
suppressor of signaling mediated by IL-1 and -3 . [30] When 
IL-1 binds to IL-IRI, a complex is formed that then binds to 
the IL-1R accessory protein (IL-1R-AcP), resulting in high 
affinity binding[34]. It is like a heterodimerization of the 
cytosolic domains of IL-1RI and IL-1R-AcP that can trigger 
IL-1 signal transduction.
In the intact peripheral nervous system, IL-1α mRNA is 
constitutively expressed, but IL-1α protein is not 
synthesized. Due to nerve injury, IL-1α is rapidly 
upregulated by SCs that have lost their close contact with 
interrupted axons. This upregulation occurs both at mRNA 
and protein levels 5 to 6 hours following damage[11]. 
The fundamental role of IL-1α in this type of injury is to 
induce the fibroblasts located on site to produce IL-6 and 
granulocyte macrophage-colony stimulating factor; the 
production of these molecules is detectable from 2 to 5 
hours after injury. 
Regarding SCs, IL-1β expression during WD is detected 
5-10 hours after injury and the delayed expression might 
be due to SC-derived TNF-α. Interestingly, the highest 
levels of TNF-α and IL-1β protein secretion were 
detected 1 day after the injury, thus before macrophage 
recruitment; in fact, it has been reported that the 
administration of a function-blocking antibody against 
IL-1β into the injured mouse sciatic nerve halts, with a 
reduction in the recruitment of macrophages and 
retarded myelin phagocytosis[35]. 
It is well known that IL-1α, IL-1β and TNF-α determine 
the first peak of nerve growth factor mRNA within hours 
after nerve injury in fibroblasts, but not in SCs ; [11]
moreover, they participate in WD by first upregulating the 
production of additional inflammatory cytokines and 
thereafter the production of anti-inflammatory 
cytokines[25]. 
 
 
IL-6 
 
IL-6 is a glycoprotein belonging to the neurokines family 
with pro-inflammatory activity, crucial in the acute 
inflammatory phase of the reaction. It enhances T-cell 
activation, and acts as a neurotrophic factor for 
cholinergic and dopaminergic neurons[36]. IL-6 plays a 
role in neuroprotection[37-38] and modulation of pain, 
binding a non-signaling α-receptor (IL-6R, also known 
as CD126), which, after dimerization with gp130, leads 
to activation of receptor-associated kinases JAK1, 
JAK2, and Tyk2. In turn, these lead to phosphorylation 
of proximal tyrosine residues within the intracellular 
portion of gp130, with subsequent control of STAT1 and 
STAT3 activity[10,39-40].  
Increased synthesis and release of cytokines, including 
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IL-6, can directly modulate neuronal activity through the 
synthesis of neuropeptide transmitters. Furthermore, 
IL-6 is a key component of the nervous system’s injury 
response. Previous studies have shown that IL-6 plays 
a role in axon regeneration after peripheral nerve injury 
and also makes an important contribution in the overall 
cellular response[41]. IL-6 level is elevated both in 
neurons and non-neuronal cells, and can increase gene 
expression of regeneration associated genes (RAGs) in 
neurons and promote neurite growth together with 
some neurotrophic factors, such as nerve growth 
factor[9]. Resident macrophages and fibroblasts of injured 
peripheral nerves are the major producers of IL6[42]. 
SC-derived IL-6 increases within 3 hours of nerve lesion 
and is required for immune cell chemotaxis within 2-5 
hours after the injury, with IL-6 secreted by 
macrophages becoming detectable[11]. IL-6 produced by 
resident fibroblast is induced by TNF-α and IL-1 
produced by SCs. 
Several studies show that the expression of IL-6 and 
IL-6 receptor α-subunit (IL-6Rα) is upregulated in 
dorsal root ganglion neurons after axonal injury and 
elongation. However, the biological actions of IL-6 
signaling on SCs have not been fully elucidated[43]. 
 
 
IL-10 
 
IL-10 is a 18.5 kDa large immunoregulatory 
anti-inflammatory cytokine secreted by a variety of cells, 
including monocytes, macrophages, dendritic cells, T 
cells, B cells, granulocytes, epithelial cells, and mast 
cells[44]. The principal routine function of IL-10 may be 
limited and ultimately terminates inflammatory 
responses[45]. In fact, IL-10 limits secretion of 
pro-inflammatory cytokines such as TNF-α, IL-1 and IL-6; 
it deactivates macrophages, inhibits secretion of Th1 
cytokines such as IL-2 and interferon-gamma, and 
controls differentiation and proliferation of macrophages, 
T cells, and B cells. While keeping pro-inflammatory 
events under control, it protects against excessive 
immune responses and tissue damage. 
There is evidence showing that IL-10 is involved in 
nerve healing process after injury. In this context, 
previous studies have shown that IL-10 plays an 
important role during nerve regeneration; in particular, 
the administration of a low dose of IL-10 to a site of 
sciatic nerve injury reduces scar formation (which is 
considered one of the main problems in nerve repair), 
and permits better regeneration of damaged axons that 
leads to greater myelination[46-47].  
Some studies have shown that the effect of IL-10 
applied at the repair site is dependent upon the 
concentration used, with no beneficial effects at high 
concentration while there was that enhanced 
regeneration of the nerve at a low concentration[47].  
The production and secretion of the anti-inflammatory 
cytokine IL-10 is induced by resident fibroblasts within 5 
hours of injury, but levels are low and ineffective because 
nerve-resident fibroblasts are poor producers, like SCs.  
To overcome this deficiency, recruited macrophages 
produce and secrete IL-10; protein levels increase, 
peaking at day 7 concomitant with the timing and 
magnitude of macrophage recruitment. IL-10 then 
gradually downregulates the production of cytokines, 
bringing the cytokine network of normal WD to a 
conclusion 2-3 weeks after injury[11]. 
 
 
OTHERS 
 
In the last part of this review, we wish to focus also on 
cytokines that remain poorly studied with regard to their 
role in peripheral nerve degeneration and regeneration.
TGF-β family comprises three isoforms in mammals: 
TGF-β1, -β2 and -β3. Moreover, the TGF-β superfamily 
has a huge number of homologous proteins[48]. Potentially, 
every cell in the body, including hematopoietic, 
endothelial, epithelial, neuronal and connective-tissue 
cells, produces TGF-β and has receptors for it. 
TGF-β-related proteins are synthesized as precursor 
proteins with an amino-terminal residue for identification 
of the signal target and a varying pro-domain that assists 
in folding, dimerization and regulation of factor activity[49]. 
As to the other components, TGF-β1, an 
anti-inflammatory cytokine, is one that is a secreted 
signalling molecule mediating many essential events of 
normal growth and development[50].  
TGF-β1 can bind at least three proteins located in the cell 
surface: type I, type II, and type III receptors, of 53, 70-85 
and 200-400 kDa, respectively[51]. Type I and type II 
receptors are the best binding molecules to transduce 
signalling pathway. TGF- β1 is the major isoform 
expressed in SCs, and this rate of expression is 
modulated by interaction with axons[52]. These authors 
also found that TGF-β1 has mitogen effects on isolated 
rat SCs, increasing the expression levels of markers of 
premyelination, neural cell adhesionmolecule, 
suppressed cAMP-inducible POU-domain protein, and 
inhibiting forskolin-induced transition to a myelinating 
phenotype. In agreement with these early observations, 
co-culture of axon and SC revealed that administration of 
TGF-β1 inhibits myelination and the correct formation 
of the basal lamina . [52-53]
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TGF-β1 expression and its effects on proliferation are 
strongly strengthened by the increased protein level 
immediately after peripheral nerve injury[54-55] and the 
following downregulation, i.e. once the nerve fibers have 
grown back into the distal stump, thus allowing 
subsequent ensheathment and myelination. 
IL-2 is a 15.5 kDa pro-inflammatory cytokine composed 
of 133 amino acids[56] that has multiple functions in the 
inflammatory response, including activation of immune 
cell effectors and stimulation of the number of white 
blood cells on the endothelial surface of skeletal muscle. 
In addition, it is a potent inducer of the proliferation, 
differentiation, development, survival, memory and 
regulatory functions of T-lymphocytes[57]. IL-2 exerts its 
biological activity by binding to the high-affinity IL-2 
receptor (IL-2R). Soluble IL-2R is part of a membrane 
receptor localized on the cell surface of different 
lymphoid cell lines, including activated T and natural 
killer cells, monocytes, eosinophils[58]. 
The IL-2R consists of 3 subunits, the α-chain (also 
known as CD25), the β-chain (CD122) and the γ-chain 
(CD132). A major function of IL-2 is to promote 
proliferation and expansion of CD4+ and CD8+ T cells 
as well as inducing the production of other cytokines[59]. 
Previous studies have shown that IL-2 in also present in 
nervous system; endogenous IL-2 and IL-2Ra occur in 
different regions of the adult rat brain, such as the 
frontal cortex, hippocampal formation, hypothalamus 
and cerebellum. Although the cellular origin of brain 
IL-2 is unclear, evidence shows that the glial cells, 
including astroglial and microglial cells, are the possible 
sources.  
Evidence has also been found that IL-2 plays multiple 
roles in the central nervous system. It has trophic 
functions on both neurons and glia. For example, IL-2, a 
neurotrophic factor for sympathetic neurons, has been 
reported to enhance the proliferation and differentiation 
of oligodendrocytes. Furthermore, IL-2 can modulate 
neurotransmitter release and affect electrical activity. It 
is also involved in responses to central nervous system 
trauma and spontaneous regeneration. Recent studies 
demonstrated that IL-2 might also play a role in spatial 
learning and memory[60]. In dorsal root ganglia neurons, 
IL-2 plays an important role in the modulation of neural 
and neuroendocrine function; furthermore, there is 
evidence to show that IL-2 has an antinociceptive 
(analgesic) effect in dorsal root ganglia by binding to 
opioid receptors[61]. 
 
OVERVIEW 
 
During WD, the orchestrated action of pro-, and 
anti-inflammatory cytokines regulates the main cellular 
and molecular events that stimulate axonal regrowth 
from proximal stumps and support axonal regeneration. 
Immediately after peripheral nerve damage, SCs, that 
have lost their contact with axons, and resident 
macrophages produce TNF-α, IL-1α and -β. These 
cytokines induce resident fibroblasts to produce IL-6[25]. 
Concomitantly, IL-6 is expressed by SCs in the early 
phases of WD; like the other cytokines, it is required for 
immune cell chemotaxis[25,59]. Following the activation of 
these cytokines, metalloproteinase, whose action is very 
important for damaged tissue remodeling, is responsible 
for basal lamina degradation, favoring destruction of the 
blood-nerve barrier and the infiltration of circulating 
macrophages[62]. Recruited cells (macrophages and T 
cells) produce inflammatory cytokines, and notably IL-10 
which attenuates the inflammatory process by inhibiting 
cytokine production of activated macrophages, 
monocytes and other cell types[45,63]. Initial production of 
pro-inflammatory cytokines at the site of a peripheral 
nerve lesion is important in influencing the long-term 
behavioral outcome of nerve injury. IL-10 may 
accomplish this by downregulating the inflammatory 
response of the nerve to injury[63]. 
TGF-β1 expressed by SCs contributes to the 
maintenance of the immature phenotype of the cells 
themselves by stimulating their proliferation and 
inhibiting the myelination of axons. Only when nerve 
fibers have grown back during nerve regeneration into the 
distal stump is TGF-β1 downregulated and myelination is 
allowed. SC-derived IL-2 promotes proliferation of T cells, 
has trophic functions on both neurons and glia, and 
induces production of other cytokines. 
Of relevance is the involvement of vitamins in nerve 
regeneration and their interaction with the inflammatory 
cytokines in the inflammatory response. Chabas and 
collegues[64] found that vitamin D potentiates axon 
regeneration, increasing axogenesis and axon diameter, 
and improving the responses of sensory neurons to 
metabolites, e.g. KCl and lactic acid.  
In vitro studies have demonstrated that vitamin D 
suppresses pro-inflammatory cytokines and increases 
anti-inflammatory cytokines[65]. Experimental evidence 
shows that vitamin D can suppress the release of TNF-α 
and effectively upregulates the synthesis of 
anti-inflammatory IL-10[66-67]. Vitamin D reduces the 
inflammatory milieu and might serve as a new 
anti-inflammatory agent in future treatment of the disorder. 
 
CONCLUSION 
 
Peripheral nerve injury leads to a characteristic series of 
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cellular and molecular events necessary for axon 
regeneration and re-innervation of target tissues[68]. 
Inflammatory reaction is one of the crucial events, being 
important for the orchestration of all the processes that 
occur during WD.  
In this review, the more studied cytokines involved in WD 
and the early phases of regeneration of a peripheral 
nerve have been outlined (TNF-α, IL-1, IL-6, IL-10). 
Attention has also been focused on two cytokines 
(TGF-α and IL-2) that are poorly described in the 
literature on peripheral nerve injury to date, which could 
make them of greater interest in the future.  
After peripheral nerve injury, pro- and anti-inflammatory 
cytokines are produced by both immune and 
non-immune cells that are resident in the distal part of 
the injured nerve or recruited from blood circulation.   
Although nowadays even the most severe nerve injury 
can be surgically repaired, complete recovery of nerve 
function does not occur and clinical results remain 
unsatisfactory. Future research could therefore address 
the issues to give better knowledge of inflammatory 
events that might help develop new therapeutic 
measures that improve and accelerate peripheral nerve 
regeneration, stimulating the endogenous 
anti-inflammatory reaction and decreasing 
pro-inflammatory processes. It is expected that a 
complete functional recovery could be achieved by 
coupling surgical repair with a pharmacological approach 
targeted to the specific molecules that trigger the 
inflammatory reaction[69-70]. 
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